Physician profile
Ute Traugott
NPI 1043380603
$81,463.36
in general payments reported to CMS, 2019-2025
10 companies · $265 in 2025
The $265 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69K · 2020: $1,947 · 2021: $8,928 · 2022: $530 · 2023: $485 · 2024: $19.34 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $415 · Education: $205 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $414.80 |
| Education | $204.65 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $46,676.54 | 2019-2023 | |
| Emd Serono, INC. | $33,378.62 | 2019-2025 | |
| Biogen, INC. | $723.25 | 2019-2023 | Tysabri, Vumerity, Plegridy |
| Genentech USA, INC. | $352.58 | 2019-2025 | Ocrevus |
| Alexion Pharmaceuticals, INC. | $162.58 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $110.94 | 2021-2024 | |
| Tg Therapeutics, INC. | $22.17 | 2023 | |
| Celgene Corporation | $15.44 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.24 | 2022 | |
| Sanofi-Aventis U.S. LLC | $7.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ute Traugott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.